ABSTRACT

Although opportunities to develop nanotechnology-based effi cient drug delivery systems extend into all therapeutic classes of pharmaceuticals, many therapeutic agents have not been successful because of their limited ability to reach the target tissue. In addition, faster growth opportunities are expected in developing delivery systems for diabetes agents, hormones and vaccines because of safety and effi cacy shortcomings with current administration modalities.